Cardiac protein abnormalities in dilated cardiomyopath polyacrylamide gel electrophoresis

Electrophoresis 19, 2031-2042 DOI: 10.1002/elps.1150191123

Citation Report

#	Article	IF	CITATIONS
1	Protein changes observed in pacing-induced heart failure using two-dimensional electrophoresis. Electrophoresis, 1998, 19, 2021-2030.	1.3	82
3	Two-dimensional map of human brain proteins. , 0, , 327-336.		0
4	In Search of the Proteins That Cause Myocardial Stunning. Circulation Research, 1999, 85, 470-472.	2.0	24
5	Bovine dilated cardiomyopathy: Proteomic analysis of an animal model of human dilated cardiomyopathy. Electrophoresis, 1999, 20, 898-906.	1.3	146
6	Two-dimensional map of human brain proteins. Electrophoresis, 1999, 20, 907-916.	1.3	147
7	Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis, 1999, 20, 2086-2093.	1.3	88
8	Rat brain proteins: Two-dimensional protein database and variations in the expression level. Electrophoresis, 1999, 20, 3572-3579.	1.3	89
9	Two-dimensional map of the proteome ofHaemophilus influenzae. Electrophoresis, 2000, 21, 411-429.	1.3	159
10	Cardiac sarcoplasmic reticulum and sarcolemmal proteins separated by two-dimensional electrophoresis: Surfactant effects on membrane solubilization. Electrophoresis, 2000, 21, 1685-1693.	1.3	32
11	Studying heart disease using the proteomic approach. Drug Discovery Today, 2000, 5, 76-84.	3.2	60
12	Effects of selenium deficiency on the rat myocardial protein pattern - investigation by two-dimensional gel electrophoresis. Basic Research in Cardiology, 2000, 95, 199-207.	2.5	1
13	Decreased SLIM1 Expression and Increased Gelsolin Expression in Failing Human Hearts Measured by High-Density Oligonucleotide Arrays. Circulation, 2000, 102, 3046-3052.	1.6	222
14	Proteomics: new perspectives, new biomedical opportunities. Lancet, The, 2000, 356, 1749-1756.	6.3	419
15	Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Letters, 2000, 480, 2-16.	1.3	291
16	Two-dimensional electrophoresis and mass spectrometric identification of mitochondrial proteins from an SH-SY5Y neuroblastoma cell line. Mitochondrion, 2001, 1, 161-179.	1.6	44
17	Protein 4.1 in forebrain postsynaptic density preparations. FEBS Journal, 2001, 268, 1084-1094.	0.2	27
18	Two-dimensional database of mouse liver proteins. An update. Electrophoresis, 2001, 22, 1747-1763.	1.3	52
19	Separation and identification of rat skeletal muscle proteins using two-dimensional gel	1.3	85

CITATION REPORT

#	Article	IF	CITATIONS
20	Application of Proteomics to the Study of Cardiovascular Biology. Trends in Cardiovascular Medicine, 2001, 11, 66-75.	2.3	47
21	A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. European Heart Journal, 2001, 22, 534-540.	1.0	155
22	Proteomics and its impact upon biomedical science. British Journal of Biomedical Science, 2002, 59, 47-64.	1.2	32
23	Identification and validation of selective upregulation of ventricular myosin light chain type 2 mRNA in idiopathic dilated cardiomyopathy. European Journal of Heart Failure, 2002, 4, 23-31.	2.9	25
24	Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiological Genomics, 2002, 10, 31-44.	1.0	220
25	Increased β-Myosin Heavy Chain in Acute Cellular Rejection Following Human Heart Transplantation. American Journal of Transplantation, 2002, 2, 386-388.	2.6	2
26	Separation and identification of human heart proteins. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 771, 131-153.	1.2	40
27	Title is missing!. Molecular and Cellular Biochemistry, 2003, 251, 145-151.	1.4	5
28	Genomics, proteomics and bioinformatics of human heart failure. Journal of Muscle Research and Cell Motility, 2003, 24, 251-261.	0.9	41
29	Proteomics in biomarker discovery and drug development. Journal of Cellular Biochemistry, 2003, 89, 868-886.	1.2	115
30	Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics, 2003, 3, 208-216.	1.3	206
32	Modifications of myosin-regulatory light chain correlate with function of stunned myocardium. Journal of Molecular and Cellular Cardiology, 2003, 35, 833-840.	0.9	42
33	Bridge to recovery with the use of left ventricular assist device and clenbuterol. Annals of Thoracic Surgery, 2003, 75, S36-S41.	0.7	83
34	Proteomics of heart disease. Human Molecular Genetics, 2003, 12, R135-R144.	1.4	72
35	Actin Binding Proteins: Regulation of Cytoskeletal Microfilaments. Physiological Reviews, 2003, 83, 433-473.	13.1	873
36	Proteomics and Hypertension. , 2003, 141, 245-256.		3
37	MURINE RETROVIRUS INFECTION AND THE EFFECT OF CHRONIC ALCOHOL CONSUMPTION: PROTEOMIC ANALYSIS OF CARDIAC PROTEIN EXPRESSION. Alcohol and Alcoholism, 2003, 38, 103-108.	0.9	10
38	Identification of biochemical adaptations in hyper- or hypocontractile hearts from phospholamban mutant mice by expression proteomics. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2241-2246.	3.3	29

#	Article	IF	Citations
39	Proteomic research: potential opportunities for clinical and physiological investigators. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E863-E874.	1.8	41
40	Genomic and Proteomic Profiles of Heart Disease. Trends in Cardiovascular Medicine, 2004, 14, 282-288.	2.3	13
41	Intregrated analysis of the human cardiac transcriptome, proteome and phosphoproteome. Proteomics, 2004, 4, 1505-1516.	1.3	31
42	Detection of regional changes in protein levels in thein vivo canine model of acute heart failure following ischemia-reperfusion injury: Functional proteomics studies. Proteomics, 2004, 4, 2195-2202.	1.3	49
43	Two-dimensional electrophoresis database ofListeria monocytogenes EGDe proteome and proteomic analysis of mid-log and stationary growth phase cells. Proteomics, 2004, 4, 3187-3201.	1.3	71
44	Two-dimensional protein database of human pancreas. Electrophoresis, 2004, 25, 512-518.	1.3	36
45	Proteomics in myocardial diseases. Pathology Research and Practice, 2004, 200, 135-145.	1.0	8
46	An effective skeletal muscle prefractionation method to remove abundant structural proteins for optimized two-dimensional gel electrophoresis. Electrophoresis, 2005, 26, 2269-2278.	1.3	21
47	Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems. Proteomics, 2005, 5, 1395-1410.	1.3	91
48	Proteomic Analysis Reveals Different Protein Changes during Endothelin-1- or Leukemic Inhibitory Factor-induced Hypertrophy of Cardiomyocytes in Vitro. Molecular and Cellular Proteomics, 2005, 4, 651-661.	2.5	36
49	P2X1 receptors are closely associated with connexin 43 in human ventricular myocardium. International Journal of Cardiology, 2005, 98, 291-297.	0.8	27
50	Alterations in the heart mitochondrial proteome in a desmin null heart failure model. Journal of Molecular and Cellular Cardiology, 2005, 38, 461-474.	0.9	57
51	Biomarkers of Cardiovascular Disease. Circulation, 2006, 113, 2335-2362.	1.6	1,030
52	Proteomics of the Heart. Circulation Research, 2006, 98, 309-321.	2.0	127
53	Application of proteomics in cardiovascular medicine. International Journal of Cardiology, 2006, 108, 12-19.	0.8	28
56	Changes in the rat heart proteome induced by exercise training: Increased abundance of heat shock protein hsp20. Proteomics, 2006, 6, 3154-3169.	1.3	66
57	Recent Developments in Proteomics: Implications for the Study of Cardiac Hypertrophy and Failure. Cell Biochemistry and Biophysics, 2006, 44, 011-030.	0.9	29
58	Cardiovascular Proteomics. Current Proteomics, 2006, 3, 147-170.	0.1	6

CITATION REPORT

	CITATIO	on Report	
#	Article	IF	Citations
59	Human Heart Failure: A Proteomics Perspective. Current Proteomics, 2007, 4, 174-181.	0.1	1
60	Possibilities of Two-Dimensional Gel Electrophoresis in the Understanding of Human Disease. Current Proteomics, 2007, 4, 187-197.	0.1	3
61	Cardiovascular Proteomics. Molecular Diagnosis and Therapy, 2007, 11, 83-95.	1.6	23
62	Patients who Have Dilated Cardiomyopathy Must Have a Trial of Bridge to Recovery (Pro). Heart Failure Clinics, 2007, 3, 299-315.	1.0	8
63	A better understanding of molecular mechanisms underlying human disease. Proteomics - Clinical Applications, 2007, 1, 983-1003.	0.8	18
64	Valsartan reverses post-translational modifications of the δ-subunit of ATP synthase duringin vivo canine reperfused myocardial infarction. Proteomics, 2007, 7, 2100-2110.	1.3	17
65	Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Research in Cardiology, 2008, 103, 431-443.	2.5	48
66	Effect of duration of ischemia on myocardial proteome in ischemia/reperfusion injury. Proteomics, 2008, 8, 2543-2555.	1.3	32
67	Proteomic profiling of endothelin-1-stimulated hypertrophic cardiomyocytes reveals the increase of four different desmin species and α-B-crystallin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 1068-1076.	1.1	24
68	Using peripheral blood mononuclear cells to determine proteome profiles in human cardiac failure. European Journal of Heart Failure, 2008, 10, 749-757.	2.9	8
69	Proteomic analysis reveals significant elevation of heat shock protein 70 in patients with chronic heart failure due to arrhythmogenic right ventricular cardiomyopathy. Molecular and Cellular Biochemistry, 2009, 332, 103-111.	1.4	37
70	Proteomics analysis of changes in myocardial proteins during endotoxemia. Journal of Proteomics, 2009, 72, 648-655.	1.2	10
71	Proteomic analysis of normal human nasal mucosa: Establishment of a two-dimensional electrophoresis reference map. Clinical Biochemistry, 2009, 42, 692-700.	0.8	7
72	Genomics and Proteomics in Heart Failure Research. Revista Espanola De Cardiologia (English Ed), 2009, 62, 305-313.	0.4	4
74	Chapter 6 Interpreting the Proteome and Peptidome in Transplantation. Advances in Clinical Chemistry, 2009, 47, 139-169.	1.8	18
75	Viral myocarditis induced by Coxsackievirus B3 in <i>A.BY</i> / <i>SnJ</i> mice: Analysis of changes in the myocardial proteome. Proteomics, 2010, 10, 1802-1818.	1.3	15
76	Proteomic Strategies for Understanding Cardiac Function, Development, and Disease. , 2010, , 793-804.		0
77	Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1220-H1225.	1.5	34

#	Article	IF	CITATIONS
78	Differential protein expression profiling of myocardial tissue in a mouse model of hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2010, 48, 1014-1022.	0.9	15
79	Characterization of the Human Myocardial Proteome in Inflammatory Dilated Cardiomyopathy by Label-free Quantitative Shotgun Proteomics of Heart Biopsies. Journal of Proteome Research, 2011, 10, 2161-2171.	1.8	66
80	Recent advances in biomarker discovery in solid organ transplant by proteomics. Expert Review of Proteomics, 2011, 8, 705-715.	1.3	24
81	Molecular Signatures of End-Stage Heart Failure. Journal of Cardiac Failure, 2011, 17, 867-874.	0.7	30
82	Role of cardiac isoform of alpha-2 macroglobulin in diabetic myocardium. Molecular and Cellular Biochemistry, 2011, 350, 229-235.	1.4	6
83	Divide and Conquer. Circulation Research, 2011, 108, 512-526.	2.0	57
84	Functional proteomic analysis reveals sex-dependent differences in structural and energy-producing myocardial proteins in rat model of alcoholic cardiomyopathy. Physiological Genomics, 2011, 43, 346-356.	1.0	22
85	Cardiac protein changes in ischaemic and dilated cardiomyopathy: a proteomic study of human left ventricular tissue. Journal of Cellular and Molecular Medicine, 2012, 16, 2471-2486.	1.6	31
86	Protein and peptide biomarkers in organ transplantation. Biomarkers in Medicine, 2012, 6, 259-271.	0.6	20
87	Proteomic analysis of metabolic, cytoskeletal and stress response proteins in human heart failure. Journal of Cellular and Molecular Medicine, 2012, 16, 59-71.	1.6	33
88	Characterization of the Human Myocardial Proteome in Dilated Cardiomyopathy by Label-Free Quantitative Shotgun Proteomics of Heart Biopsies. Methods in Molecular Biology, 2013, 1005, 67-76.	0.4	1
89	Novel proteins associated with human dilated cardiomyopathy: selective reduction in α1A-adrenergic receptors and increased desensitization proteins. Journal of Receptor and Signal Transduction Research, 2013, 33, 96-106.	1.3	11
90	Desmin modifications associate with amyloid-like oligomers deposition in heart failure. Cardiovascular Research, 2014, 102, 24-34.	1.8	71
91	Cardiac protein changes in rats after soybean oil treatment: a proteomic study. Lipids in Health and Disease, 2015, 14, 26.	1.2	3
92	Right Ventricular Protein Expression Profile in End‣tage Heart Failure. Pulmonary Circulation, 2015, 5, 481-497.	0.8	19
93	Undiscovered Physiology of Transcript and Protein Networks. , 2016, 6, 1851-1872.		0
94	Delineation of Molecular Pathways Involved in Cardiomyopathies Caused by Troponin T Mutations. Molecular and Cellular Proteomics, 2016, 15, 1962-1981.	2.5	9
95	Ups and downs in heart failure: the case of proteomics. European Journal of Heart Failure, 2018, 20, 63-66.	2.9	6

CITATION REPORT

	CITATION	CITATION REPORT		
#	Article	IF	Citations	
96	Is Desmin Propensity to Aggregate Part of its Protective Function?. Cells, 2020, 9, 491.	1.8	19	
97	MudPIT Analysis: Application to Human Heart Tissue. Methods in Molecular Biology, 2009, 528, 281-293.	0.4	26	
98	Proteomic inventory of myocardial proteins from patients with chronic Chagas' cardiomyopathy. Brazilian Journal of Medical and Biological Research, 2006, 39, 1549-1562.	0.7	23	
99	Proteomic analysis identifies mitochondrial metabolic enzymes as major discriminators between different stages of the failing human myocardium. Acta Cardiologica, 2009, 64, 511-522.	0.3	12	
100	Posttranslational Modifications of Myosin Light Chains Determine the Protein Fate. , 0, , .		1	
101	Proteomic analysis of Rac1 transgenic mice displaying dilated cardiomyopathy reveals an increase in creatine kinase M-chain protein abundance. , 2003, , 145-151.		4	
104	Myocardial Recovery Following LVAD Support. , 2008, , 733-760.		0	
105	A Historical Perspective on Cardiovascular Proteomics. , 2016, , 1-14.		0	
106	Proteomic Technologies and Application to the Study of Heart Disease. , 2004, , 19-55.		0	
107	Proteomic analysis of Rac1 transgenic mice displaying dilated cardiomyopathy reveals an increase in creatine kinase M-chain protein abundance. Molecular and Cellular Biochemistry, 2003, 251, 145-51.	1.4	3	
108	Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF). Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	5	